Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients
-
Published:2019-02-26
Issue:10
Volume:21
Page:734-748
-
ISSN:1386-2073
-
Container-title:Combinatorial Chemistry & High Throughput Screening
-
language:en
-
Short-container-title:CCHTS
Author:
Guo Baoling1, Zheng Qiuxiang1
Affiliation:
1. Department of Oncology, Longyan First Hospital, Affiliated to Fujian Medical University, Longyan, China
Abstract
Aim and Objective:
Lung cancer is a highly heterogeneous cancer, due to the significant
differences in molecular levels, resulting in different clinical manifestations of lung cancer patients
there is a big difference. Including disease characterization, drug response, the risk of recurrence,
survival, etc.
Method:
Clinical patients with lung cancer do not have yet particularly effective treatment options,
while patients with lung cancer resistance not only delayed the treatment cycle but also caused strong
side effects. Therefore, if we can sum up the abnormalities of functional level from the molecular
level, we can scientifically and effectively evaluate the patients' sensitivity to treatment and make the
personalized treatment strategies to avoid the side effects caused by over-treatment and improve the
prognosis.
Result & Conclusion:
According to the different sensitivities of lung cancer patients to drug
response, this study screened out genes that were significantly associated with drug resistance. The
bayes model was used to assess patient resistance.
Publisher
Bentham Science Publishers Ltd.
Subject
Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine
Reference13 articles.
1. McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. 2. Collisson E. Comprehensive molecular profiling of lung adenocarcinoma. 3. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van’t Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Benz CC, Perou CM, Stuart JM. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. 4. Vayshlya Na. Increased expression of BIRC5 in non-small cell lung cancer and esophageal squamous cell carcinoma does not correlate with the expression of its inhibitors SMAC/DIABLO and PML. 5. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, Vartanian S, Walter K, Chan J, Holcomb T, Dijkgraaf P, Johnson S, Koeman J, Minna JD, Gazdar AF, Stern HM, Hoeflich KP, Wu TD, Settleman J, de Sauvage FJ, Gentleman RC, Neve RM, Stokoe D, Modrusan Z, Seshagiri S, Shames DS, Zhang Z. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|